fda glp 1 Hims Inc Novo pressures GLP-1 compounders as

[DOI] [PubMed] [Google Scholar] 123.White W.B., Cannon C.P., Heller S.R., Nissen S.E., Bergenstal R.M., Bakris G.L

Additionally, lixisenatide was associated with fewer gastrointestinal symptoms compared to exenatide, while long-acting GLP-1RAs generally caused less nausea and vomiting but more diarrhea than short-acting agents (49)

Goal: Type 2 diabetes management (A1C reduction) If you prefer once-weekly injections: Semaglutide (Ozempic), tirzepatide (Mounjaro), dulaglutide (Trulicity), or efpeglenatide (Eperzan) If you prefer daily injections: Liraglutide (Victoza) or lixisenatide (Adlyxin) If you prefer oral medication: Semaglutide (Rybelsus) If cost is the primary concern: Compounded semaglutide or compounded tirzepatide (if eligible under shortage provisions) Goal: Weight loss (obesity or overweight with comorbidities) If you want maximum weight loss: Retatrutide (Retara, triple agonist, 24% mean loss) or tirzepatide (Zepbound, dual agonist, 20% to 22% mean loss) If you want proven long-term safety data: Semaglutide (Wegovy, 15% to 17% mean loss, 5+ years post-approval data) If you prefer oral medication: Orforglipron (Orfoglip, 15% mean loss, oral once daily) If cost is the primary concern: Compounded semaglutide or compounded tirzepatide Goal: Both diabetes and weight loss If you have significant obesity (BMI over 35): Tirzepatide (Mounjaro for diabetes indication, Zepbound for obesity indication

Cardiorenal Impact of SGLT-2 Inhibitors: A Conceptual Revolution in The Management of Type 2 Diabetes, Heart Failure and Chronic Kidney Disease

The CCI was modified to exclude kidney disease and late-diabetic complications, as these covariates were separately adjusted for in the statistical analyses

GLP-1s have seen unparalleled launch success despite the controls in place in the market